Dow Jones 30 Industrial Paper Walt Disney Share: This is how much investors would have earned with an investment in Walt Disney 10 years ago ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

The main growth driver for Eli Lilly is the successful incretin portfolio, specifically the duo Mounjaro and Zepbound. Mounjaro's Q3 2024 performance was nothing short of exceptional, with global ...

Eli Lilly announced preliminary ... for diabetes drug Mounjaro and obesity drug Zepbound. Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in sales ...